TG Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.9%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$960.2Mnext fiscal year
FY EPS (est.)
$0.95next fiscal year
Monitoring Framework
Key Performance Indicators
BRIUMVI U.S. Net Product Revenue Quarterly194.8MTarget: $885 million to $900 million for FY 2026
Total Global Revenue Quarterly204.9MTarget: $875 million to $900 million for FY 2026 (prior guidance)
Watch Items
- Subcutaneous (SC) BRIUMVI Phase 3 Trial ProgressTrigger: Completion of Phase 3 non-inferiority exposure dataAction: Evaluate clinical data to support regulatory filings for at-home self-administered dosing
- Consolidated IV BRIUMVI Dosing sBLA SubmissionTrigger: Submission of supplemental Biologics License Application (sBLA) in 2H 2026Action: Monitor FDA review timeline for the single 600 mg IV dose regimen
- Pipeline Expansion into Autoimmune and Neurological IndicationsTrigger: Initiation of Phase II study of Briumvi in Schizophrenia and progress of azer-cel in progressive MSAction: Track clinical trial milestones and patient enrollment rates
Research as of 28 Jul 2026